Impact BioMedical Inc.: 1-for-12.62 reverse stock split

What happened

• The company filed a Certificate of Amendment to its Certificate of Incorporation to effect a one-for-twelve point six two (1-for-12.62) reverse stock split of its issued and outstanding common stock. The Reverse Stock Split became effective Sep 23, 2026 at 12:01 A.M. EST and began trading on a split-adjusted basis on Sep 23, 2026 under the existing ticker symbol "IBO" on the New York Stock Exchange American with a new CUSIP of 45259L304.
• The Board approved authorization for a reverse stock split on Nov 24, 2025, and the stockholders approved the proposal on Dec 30, 2025. The Company submitted the Amendment for filing on Sep 23, 2026 but did not receive the file-stamped Amendment from the Nevada Secretary of State until Oct 6, 2026 due to a clerical processing error; the company has been in contact with the New York Stock Exchange American regarding this timing.

Key details

• The Reverse Stock Split combined every 12.62 pre-split shares into 1 post-split share.
• Shares issued and outstanding were reduced from approximately 107.8 million to approximately 8.6 million.
• No fractional shares were issued; holders otherwise entitled to fractional shares received one full post-split share instead.
• Equiniti Transfer & Trust Company is acting as exchange agent; registered book-entry holders need not take action and broker-held positions will be adjusted subject to brokers' processes.

Why it may matter

• Item reported: Item 5.03 (Amendments to articles of incorporation or bylaws). This item covers the filing of a Certificate of Amendment to the Company’s Certificate of Incorporation to effect the reverse stock split described above.
• The filing does not show why the insider traded or why the company acted.